Evidence map›Paper›PMID 41452488›Full record

ArticleMedical oncology (Northwood, London, England)2025

Engineered pluronic nanomicelles containing ATRA and sodium butyrate for selective TNBC differentiation therapy.

Abolfazl Doustmihan, Mehdi Jaymand, Marziyeh Fathi, Rana Jahanban Esfahlan

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Abolfazl DoustmihanDepartment of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Mehdi JaymandNano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Marziyeh FathiResearch Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran. fathi.marziyeh@yahoo.com.
Rana Jahanban EsfahlanDepartment of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. rana.jahanban@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We formulated a micellar nanosystem for selective differentiation therapy of breast cancer stem cells (BCSCs). Hyaluronic acid (HA) coating was used to target CD44

Indexed as

Breast NeoplasmsPoloxamerTretinoinCell DifferentiationCell Line, TumorDrug Resistance, NeoplasmFemaleHumansHyaluronic AcidMCF-7 CellsMicellesNanoparticlesNeoplastic Stem CellsReceptors, Retinoic AcidHyaluronic AcidMicellesPoloxamerReceptors, Retinoic Acidretinoic acid receptor betaTretinoinBreast cancerCancer stem cellDifferentiation therapyEpigeneticNanomicell

Identifiers

PMID41452488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.